Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Authors: Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith - The Lancet 2012 cited by 558